Thybon Henning

Quick links to important sections

Thybon Henning

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Thybon Henning

This section provides a factual overview of Thybon Henning, defining its composition, type, and pharmacological class.

Property Description
Active Ingredient Liothyronine (as the hydrochloride salt)
Form Oral tablet
Pharmacological Class Thyroid hormone (Thyronine)
Type Synthetic T3 Monopreparation
Manufacturer Sanofi-Aventis (European distribution)

What is Thybon Henning?

Thybon Henning is a prescription-only synthetic medicine, classified as a thyroid agent, used to replace the natural thyroid hormone triiodothyronine (T3). It is manufactured by Sanofi-Aventis and is provided as an oral tablet for systemic administration, primarily serving the German and broader European markets.

The active substance is liothyronine sodium, which is structurally identical to the T3 hormone produced naturally by the body. This product is a monopreparation, containing only the active T3 form, distinguishing it from combination therapies. Liothyronine acts as a direct replacement for this hormone, which is essential for maintaining the body's metabolic processes.


What is the Active Ingredient and Class?

The active ingredient in Thybon Henning is liothyronine, categorized as a thyronine within the pharmacological class of thyroid hormone replacement drugs. Liothyronine is the metabolically active component, providing the final hormone directly, which is why it is recognized for its rapid onset of action compared to levothyroxine (T4).

This rapid effect is a key characteristic of pure T3 agents, which are suitable for certain clinical needs, such as managing short-term hormonal deficiencies or specific diagnostic procedures. Due to its nature, liothyronine is classified as a Narrow Therapeutic Index (NTI) drug, meaning its blood concentration requires precise management.

Regulatory References

  1. Liothyronine: MedlinePlus Drug Information

What side effects are possible with Thybon Henning?

The safety profile of Thybon Henning, which contains liothyronine, is primarily structured around adverse reactions that are indicative of therapeutic over-replacement and resemble symptoms of hyperthyroidism, meaning the effects are largely dose-dependent.


Adverse Reaction Scope

The most common adverse effects documented in regulatory labeling involve the cardiac and nervous systems. These generally include palpitations, tachycardia (rapid heart rate), headache, nervousness, anxiety, tremor, insomnia, and increased sweating. Weight loss, diarrhea, and menstrual irregularities are also listed.

Frequency classification (Not Known): The majority of these adverse reactions are classified as “Not Known” in the European Summary of Product Characteristics (SmPC), as their frequency cannot be reliably estimated from available data and is strongly linked to the administered dosage.

Serious Adverse Reactions (Label-Documented):

  • Cardiac Events: Official documents specify that overtreatment may precipitate or worsen angina, cardiac arrhythmias, or myocardial infarction (heart attack), particularly in susceptible patients.
  • Acute Adrenal Crisis: Starting therapy prior to correcting pre-existing, uncorrected adrenal insufficiency may precipitate a life-threatening acute adrenal crisis.

Population-Specific Safety Considerations:

  • Older Adults and Cardiovascular Disease: Patients in these groups have a documented greater risk for serious cardiac adverse reactions from thyroid hormone over-replacement.
  • Long-Term Exposure: Prolonged treatment with doses exceeding required levels is associated with a risk of decreased bone mineral density (osteoporosis), especially in post-menopausal women.

Safety-Related Restrictions

Contraindications: The medicine is formally restricted from use in individuals with untreated thyrotoxicosis (overactive thyroid) and uncorrected adrenal cortical insufficiency. The medicine is also restricted from use solely for the treatment of obesity or weight reduction in individuals with normal thyroid function, as this may lead to serious toxicity.

Connection to the overall safety profile: The official safety information structures the understanding of risks by focusing on the consequences of excessive hormonal activity, particularly the vulnerability of the cardiovascular system. This dictates the safety approach in older patients and those with pre-existing heart conditions.

Overdose and Emergency Response

Overdose and when to seek help

Overdose Scope

Overdosage of liothyronine, the active component in Thybon Henning, is officially documented as presenting with clinical signs that mirror hyperthyroidism or thyrotoxicosis due to excess hormone exposure. Documented manifestations involve the Cardiovascular, Central Nervous System (CNS), Metabolic, and Gastrointestinal systems. Common signs of toxicity include arrhythmias (irregular heartbeat), nervousness, tremors, insomnia, weight loss, diarrhea, and heat intolerance. Toxicity may not necessarily be evident or may be delayed for several days after ingestion, requiring awareness of this potential time lag.

Severe Outcomes and Emergency Action

Larger doses can produce serious or even life-threatening manifestations of toxicity, with reported severe outcomes including myocardial infarction, shock, seizure, and severe cardiac arrhythmias. For this reason, regulatory guidance mandates that patients or caregivers seek immediate medical assistance if symptoms of toxicity occur or are suspected. It is specifically directed to contact a Poison Control center or emergency services immediately in case of overdose.

Management and Monitoring

Management of overdosage is symptomatic and supportive treatment. This may involve the use of activated charcoal, and it requires careful monitoring of vital signs and cardiac function (e.g., ECG). Specific populations carry documented risks: elderly patients and those with underlying cardiovascular disease have an increased risk of severe cardiac adverse reactions. In infants, excessive doses may produce craniosynostosis (premature skull fusion).

Therapeutic Uses of Thybon Henning

Main Uses of Thybon Henning

Thybon Henning is a synthetic form of the thyroid hormone triiodothyronine (T3). It is primarily used to address conditions where the thyroid gland does not produce sufficient levels of hormones to meet the body's metabolic demands.

Treatment of Hypothyroidism

The medication is used to treat various forms of hypothyroidism, a condition characterized by an underactive thyroid. By providing a direct source of T3, the active form of thyroid hormone, it helps to restore hormonal balance in patients who have a deficiency.

Combination Therapy

In many clinical settings, Thybon Henning is utilized as part of a combination therapy alongside levothyroxine (T4). While the body normally converts T4 into T3, some individuals may continue to experience symptoms of hypothyroidism despite having normal T4 levels. In these cases, the addition of T3 aims to more closely mimic the natural physiological output of a healthy thyroid gland.

Thyroid Suppressive Therapy and Diagnostics

Thybon Henning may be used in thyroid suppression tests to help differentiate between various types of thyroid disorders. It is also employed in the management of thyroid-dependent tumors, where suppressing the production of thyroid-stimulating hormone (TSH) is a necessary part of the therapeutic strategy.

Benefits and Physiological Impact

As the most biologically active thyroid hormone, the T3 provided by Thybon Henning acts quickly to regulate the body's energy use and metabolic rate.

Metabolic Regulation

The primary benefit of treatment is the normalization of metabolic processes. This includes the regulation of body temperature, heart rate, and the efficiency with which the body converts nutrients into energy.

Symptom Management

By restoring adequate hormone levels, the medication helps alleviate the common clinical manifestations of hypothyroidism, such as:

  • Persistent fatigue and lethargy
  • Sensitivity to cold temperatures
  • Cognitive changes, often described as "brain fog"
  • Physical changes like dry skin or thinning hair

Rapid Onset of Action

Unlike T4-only medications, which require time for the body to convert the hormone into its active form, T3 is immediately available for use by the body's cells. This characteristic is particularly beneficial in acute situations or for patients with specific metabolic impairments that hinder effective hormone conversion.

Regulatory References

  1. MedlinePlus Drug Information

Eligibility and Restrictions for Use

Thybon Henning (Liothyronine Sodium) is approved for use as thyroid hormone replacement therapy in adults and children of all ages who have primary, secondary, or tertiary hypothyroidism, including myxedema. It is also approved for pituitary TSH suppression.


Official Regulatory Exclusions (Contraindications)

Category Official Regulatory Statement
Absolute Contraindications Use is prohibited in patients with uncorrected adrenal cortical insufficiency, untreated thyrotoxicosis, hypersensitivity to the drug’s components, established myocardial ischemia, or acute myocardial infarction [DailyMed - NIH; UK Liothyronine SmPC].
Prohibited Use The medicine must not be used for the treatment of obesity or for weight loss in euthyroid patients [DailyMed - NIH; FDA].

Restricted and Conditional Use

Certain groups may be eligible only under specific, cautious conditions established in official labeling.

  • Geriatric and Cardiac Status: Use requires great caution in the elderly and in patients with known or suspected underlying cardiovascular disease, such as angina [DailyMed - NIH].
  • Concomitant Endocrine Conditions: Adrenal insufficiency must be corrected with glucocorticoid therapy prior to initiating liothyronine [UK Liothyronine SmPC].
  • Pregnancy and Lactation: The US FDA classifies use during pregnancy as acceptable. However, some European regulators note T4 (levothyroxine) is generally preferred for replacement therapy in pregnancy. Use during lactation requires caution [Pfizer Medical - US; NIH LactMed].

What should I know about interactions with other medicines?

Interactions with other medicines and products — official regulatory information for Thybon Henning


Interaction Scope

Medicinal product categories with documented interactions:

  • Adrenocortical Steroids (Glucocorticoids)
  • Antidiabetic Agents (Insulin, Oral Hypoglycemics)
  • Sympathomimetic Amines
  • Cation-Binding Agents (Antacids, Bile Acid Sequestrants)

Timing-based interaction rules: Liothyronine administration must be separated by at least four hours from the administration of Cation-Binding Agents, Iron Salts, and Calcium Supplements to mitigate reduced oral absorption of the thyroid hormone.

Interaction-related restrictions: Therapy is contraindicated for initiation in patients with uncorrected adrenal cortical insufficiency due to the risk of precipitating an acute adrenal crisis.


Interaction Classifications (High-Level)

Interaction severity classification (as defined in official documents):

  • Contraindicated: Initiation in uncorrected adrenal insufficiency.
  • Clinically Significant: Antidiabetic Agents and Cation-Binding Agents.

Population-specific interaction notes: Patients with adrenal insufficiency require glucocorticoid replacement therapy prior to starting treatment. Patients with diabetes mellitus may require adjustments to their antidiabetic regimen due to the drug's effect on glycemic control.


Resulting interaction structure

Official regulatory documentation establishes that Thybon Henning modifies the body’s systemic processes, leading to two primary interaction types: pharmacokinetic interference and metabolic modification. The pharmacokinetic profile necessitates a mandatory timing rule to prevent cation-binding agents from significantly reducing drug exposure. The metabolic interaction profile requires careful management of concurrent glucocorticoid and antidiabetic therapies due to the drug's effect on their clearance and efficacy.

Mechanism of Action

Thybon Henning, containing liothyronine (L-triiodothyronine or T3), functions as an agonist for the nuclear Thyroid Hormone Receptors ( TRs), specifically TRalpha and TRbeta. Liothyronine is the most biologically active form of thyroid hormone.

Upon cellular entry via specific membrane transporters, T3 diffuses across the cytoplasm to the cell nucleus. Inside the nucleus, T3 binds to the unliganded TR homodimer or heterodimer (often paired with the Retinoic Acid Receptor, RXR) which is bound to a Thyroid Hormone Response Element ( TRE) on the DNA.

Binding of T3 causes a conformational change in the TR complex, leading to the dissociation of corepressor proteins and the recruitment of coactivator proteins. This molecular switch modulates the transcription of a vast number of genes, including those encoding proteins crucial for cellular respiration, lipolysis, gluconeogenesis, and myocyte contractility.

These intracellular cascades result in a system-level modulation of Basal Metabolic Rate ( BMR) by enhancing oxygen consumption and heat production, and by regulating the metabolism of carbohydrates and lipids across various tissues.

Dosage and Administration Information

How to Use Thybon Henning: Official Administration Guidelines

Administration of Thybon Henning (Liothyronine Sodium) is primarily by the oral route using the tablet formulation for replacement therapy. While this is the standard form, an intravenous solution exists for highly specific, critical scenarios, such as myxedema coma. The core principle of use is a slow, gradual increase to the maintenance dose.

Dosing Schedule and Frequency

For adult patients with hypothyroidism, treatment is generally initiated with a low starting dose of 25 micrograms (mcg) taken once daily. The dosage is then increased slowly, typically by increments of 12.5 mcg or 25 mcg every one to two weeks, until the required maintenance dose is reached, which often falls in the range of 25 mcg to 75 mcg daily. The medication should be administered orally with fluid.

Population-Specific Rules and Special Conditions

Guidelines typically specify a lower starting dose of 5 mcg once daily for older adults or individuals with underlying cardiac disease. For these groups, dose increases are generally restricted to no more than 5 mcg at two-week intervals. Regarding timing, if a dose is missed, a person should not take an extra dose to compensate, but should continue with the next scheduled dose. For specific diagnostic purposes, such as the thyroid suppression test, a higher dose of 75 mcg to 100 mcg is administered for a short-term course of seven days. Additionally, when required for patients with swallowing difficulties, the tablet may be crushed and dispersed in a small amount of water for immediate ingestion.

Recent Clinical Evidence

Thybon Henning: Recent Clinical Evidence

This section summarizes the structure of the available clinical research and studies for Thybon Henning (Liothyronine). It focuses on what research has explored and what the findings describe, without making any claims about the medicine's performance or providing clinical advice.


Evidence for Use in Severe Chronic Thyroid Deficiency

Liothyronine was studied for use as a replacement for the body's natural thyroid hormone, especially in acute and severe deficiency states, such as Myxoedema Coma. The knowledge base for this use primarily relies on historical clinical data and long-term observational evidence. Research has examined outcomes related to restoration of thyroid hormone action and the normalization of TSH levels.

The overall evidence base describes Liothyronine's role as a replacement agent for thyroid hormone. Studies documented the observation of TSH normalization and changes in clinical status in acute deficiency settings. The evidence landscape for standard chronic maintenance is different, as comparative evidence is lacking for routine, long-term monotherapy use.


Research Landscape for Persistent Symptoms in Hypothyroidism

Research has explored giving Liothyronine in combination with Levothyroxine (T4/T3 combination therapy) to adults who continued to report symptoms like fatigue and depression despite regulated TSH levels. The dominant study designs used were highly controlled double-blind, crossover Randomized Controlled Trials (RCTs).

Researchers examined a wide range of outcomes, including Patient-Reported Outcomes (PROs) for Quality of Life and specific symptom scores. Findings across the synthesized RCTs for this combination protocol were mixed and often inconsistent. The majority of studies found no statistically significant differences in measures like overall Quality of Life or Fatigue scales when compared to standard treatment alone.

Key uncertainties include the absence of a consistently identified subgroup of symptomatic patients who derive measurable changes. Limited long-term data is available to characterize effects beyond one year.

Key Studies & References

  1. Label: LIOTHYRONINE SODIUM tablet - DailyMed (US Regulatory Monograph)
  2. Public Assessment Report National Procedure Liothyronine Sodium 20 micrograms Tablets (liothyronine sodium) - UK Regulatory Assessment
  3. Liothyronine: MedlinePlus Drug Information (Patient and General Authority Context)

Frequently Asked Questions (FAQ)

Common questions about Thybon Henning (FAQ)


Q: How is Thybon Henning different from levothyroxine?

Official documents describe Thybon Henning (liothyronine) as containing the active thyroid hormone T3, while levothyroxine contains the less active prohormone T4. T3 is recognized in medical literature for having a more rapid onset of action compared to T4.


Q: Why do some people switch from T4-only drugs to T3-containing drugs like Thybon Henning?

Official documents state Thybon Henning's primary purpose is thyroid hormone replacement, but it is also approved for pituitary TSH suppression. Additionally, clinical studies have examined the use of liothyronine in combination with T4 for patients who reported persistent symptoms, such as fatigue, despite regulated T4 treatment alone.


Q: How quickly should someone expect to notice the effects of Thybon Henning?

Liothyronine, the active component, is known in medical literature for its rapid onset of action. Studies examining the drug's absorption indicate that maximum concentrations in the blood are typically reached approximately 2.5 hours after taking the medication.


Q: Is Thybon Henning used to treat conditions other than hypothyroidism?

Official regulatory documents indicate that Thybon Henning is approved for use in pituitary TSH suppression in addition to its primary use as hormone replacement therapy for hypothyroidism.


Q: Is Thybon Henning safe to take during pregnancy?

The U.S. FDA lists liothyronine for use as replacement therapy during pregnancy. However, some European regulatory bodies note that T4 (levothyroxine) is generally preferred for replacement therapy in pregnancy.


Q: How long is a patient typically on Thybon Henning treatment?

For the chronic condition of hypothyroidism, treatment is described in official documents as generally requiring long-term or lifelong replacement therapy. The drug is also approved for short-term use when needed for specific diagnostic procedures.


Q: What happens if I accidentally take two doses of Thybon Henning?

Regulatory information focuses on the risk of signs resembling hyperthyroidism, which are indicative of therapeutic over-replacement. These signs can include palpitations, rapid heart rate, nervousness, and tremor. Overtreatment may precipitate serious cardiac events in susceptible patients.


Q: What does 'use conditions' mean in relation to Thybon Henning?

In official documents, 'use conditions' refers to the approved purpose of the drug (replacement and TSH suppression), the patient groups who are eligible or restricted from use (contraindications), and the mandatory rules for administration (timing and dosage adjustment for specific populations).


Q: How does the drug's purpose relate to thyroid cancer treatment?

Thybon Henning is officially approved for pituitary TSH suppression. In certain clinical settings, such as after treatment for thyroid cancer, suppressing TSH is described in clinical settings as the intended therapeutic goal.


Q: Are there certain foods or drinks that should be avoided when taking Thybon Henning?

Official instructions primarily mandate separating the medication from supplements like iron and calcium by at least four hours. Official guidance often recommends administration on an empty stomach with fluid to support consistent absorption. Some foods, like soy products, walnuts, and high-fiber foods, are commonly noted in regulatory literature to potentially affect the absorption of other thyroid hormones.


Q: Does Thybon Henning interact with birth control pills?

Official medical literature describes that oral contraceptives containing estrogen can affect how the body manages thyroid hormones by changing the proteins that bind them in the blood. This interaction may necessitate adjustments to the thyroid hormone regimen and careful monitoring.


Q: What are the known interactions between Thybon Henning and blood thinners?

Official documents describe that thyroid hormones, including liothyronine, can potentiate the effects of blood thinners such as warfarin. Official regulatory information notes that this interaction can necessitate adjustments to the blood thinner dosage and careful monitoring.


Q: Why is it important to have blood tests while on Thybon Henning?

Blood monitoring is described in regulatory instructions as necessary because the use guidelines are based on gradually achieving a state where hormone levels are normalized. Official dosing guidelines are built on adjusting the dose to maintain appropriate levels of T3 and T4 and suppress TSH to the desired range.


Q: Can I take Thybon Henning if I have a known allergy to iodine?

Thyroid hormone, including liothyronine, is a molecule that naturally contains iodine as an essential part of its chemical structure. An allergic reaction to the drug itself (hypersensitivity to any component) is a contraindication as defined in official documents.


Q: Does Thybon Henning have a black box warning from regulatory bodies?

Regulatory documents, such as the U.S. FDA labeling, contain a Boxed Warning for liothyronine. This warning explicitly states that the drug must not be used for the treatment of obesity or for weight loss in patients who have normal thyroid function.


Q: Can I stop taking Thybon Henning suddenly?

Since Thybon Henning is a replacement therapy for a chronic condition, abruptly stopping the medication will result in a return to the hypothyroid state. This will cause the associated signs and symptoms of low thyroid hormone levels to reappear.


Q: How is Thybon Henning linked to cholesterol levels?

Thyroid hormones are described in medical literature as having a strong influence on the regulation of cholesterol and lipid metabolism. Hypothyroidism, the condition Thybon Henning treats, is often associated with elevated levels of LDL cholesterol.


Q: Is Thybon Henning known to interact with caffeine?

Information related to other oral thyroid hormone medications suggests that beverages containing caffeine may reduce the absorption of the medicine if taken too closely together. For optimal consistency, regulatory guidance often recommends administration on an empty stomach with water.

How should Thybon Henning be stored and disposed of?

Mandatory Storage Conditions

Thybon Henning (liothyronine sodium) tablets must be stored at Controlled Room Temperature, maintained between 15 C and 30 C (59 F and 86 F). The product must be protected from heat, moisture, and direct light, and it is essential to keep the medicine from freezing.

Handling and Disposal

The tablets must be kept in a closed container or the original package. For safety, the medicine must always be stored out of the reach of children. Unused or expired product should not be discarded in household trash or wastewater. Patients must ask a healthcare professional or pharmacist for instructions on proper disposal of the medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Thybon Henning found in:

A-Z Index: